Breast cancer drug licensed for women in early stage of disease

A breast cancer drug that almost doubles the eradication of tumours and extends survival has been licensed for early stages of the disease. Perjeta, which is used in women with HER2-positive breast cancer prior to surgery, is already licensed for those whose cancer has spread around the body.